D

ivining what President Trump is thinking is not always an easy task, but biotech executive John Crowley believes he may have some insight — at least when it comes to Trump’s views on the Food and Drug Administration.

Earlier this week, Trump gave a major speech vowing to “slash restraints” at the FDA to speed drug approvals and he has previously promised to get rid 75 percent to 80 percent of regulations. Crowley is no mind reader, but after a private meeting with Trump at the White House before the speech, he came away with the impression that the president does not really want to unravel the FDA.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

  • After a “private meeting” Prime Minister May also thought she had an idea that Our Dear Leader would be supportive. Good luck with that.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.